Predictors of response to pegylated interferon in chronic hepatitis B: a real-world hospital-based analysis

Citations Over TimeTop 10% of 2016 papers

Abstract

Information on the efficacy of pegylated interferon (PEG-IFN) treatment of chronic hepatitis B (CHB) patients and predictors of the response based on real-world data is limited. Consecutive 201 patients who underwent PEG-IFN treatment for CHB were reviewed. A virological response (VR) was defined as a serum HBV DNA of <2000 IU/mL, and a combined response (CR) was defined a VR accompanied by serological response for hepatitis B e antigen (HBeAg)-positive CHB. For HBeAg-positive CHB patients, the HBeAg seroconversion rate and CR rate were 30.5% and 21.2% at 48 weeks after end of treatment (EOT), respectively. Baseline alanine aminotransferase (ALT) level was associated with HBeAg seroconversion, while baseline hepatitis B s antigen (HBsAg) levels of <250 IU/mL and HBV DNA <2.5 × 10(7) IU/mL were strongly associated with sustained off-treatment CR. For HBeAg-negative CHB, the VR rates were 85.5%, and 27.7% at EOT, and 48 weeks after EOT, respectively; a baseline HBsAg <1,250 IU/mL was associated with sustained off-treatment VR. PEG-IFN treatment has durable HBeAg seroconversion in HBeAg-positive CHB, but results in a high risk of relapse among HBeAg-negative CHB patients. Pre-treatment HBsAg level is an important predictor of VR in CHB patients undergoing PEG-IFN treatment.

Related Papers

• → HBcrAg, pg RNA and HBsAg dynamically supervise the seroconversion of HBsAg with anti-viral therapy(2019)14 cited
• → Experimental study of the inhibitory effect of gantai capsule on HBsAg and HBeAg expression(2002)1 cited
• Inhibition of HBsAg and HBeAg Expression by ASODN of Various Regions of the HBV Genome(2005)
• Inhibitory effect of extracts of the core of lithion the expression of HBsAg and HBeAg in the HepG 2.2.15 cells(2004)
• Inhibitory effect of FFYC tablets(FFYC) on expression of HBsAg and HBeAg(2004)